A biopsychosocial approach to improving quality of life in Tardive Dystonia

Journal of Psychiatric Practice

Volumn 16, Issue 5, 2010, Pages 350-357

  Buscombe, Charlotte ^b   Alusi, Sundus H ^c   Kahn, David A ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c College of Physicians and Surgeons ^*  (United States)

Author keywords

book review; forensic psychiatry; textbooks

Indexed keywords

ALPHA TOCOPHEROL; BACLOFEN; BOTULINUM TOXIN; CLONAZEPAM; CLOZAPINE; DIAZEPAM; LOFEPRAMINE; METOCLOPRAMIDE; OLANZAPINE; RISPERIDONE; ZOPICLONE;

ADULT; ANXIETY DISORDER; ARTICLE; BASAL GANGLION; BRAIN DEPTH STIMULATION; CASE REPORT; CHRONIC PAIN; CLINICAL PRACTICE; COGNITIVE THERAPY; DEPRESSION; DISEASE SEVERITY; DYSTONIA; ELECTROENCEPHALOGRAM; FACE MUSCLE; FEMALE; HUMAN; IRRITABLE COLON; NAUSEA; NECK MUSCLE; NEUROPATHIC PAIN; PHYSIOTHERAPY; PROGNOSIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL SUPPORT; SPEECH DISORDER; SUICIDE ATTEMPT; TARDIVE DYSTONIA; TORTICOLLIS; TRANSCUTANEOUS NERVE STIMULATION;

ANTIEMETICS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; METOCLOPRAMIDE; MIDDLE AGED; MOVEMENT DISORDERS; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 77957606590     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000388631.67275.16     Document Type: Article

References (29)

1. Adityanjee, Aderibibe YA, Jampala VC, et al. The current status of tardive dystonia. Biol Psychiatry 1999;45:715-30.
2. van Harten PN, Kahn RS. Tardive dystonia. Schizophr Bull 1999;25:741-8.
3. Lim VK. Health related quality of life in patients with dys-tonia and their caregivers in New Zealand and Australia. Mov Disord 2007;22:998-1003.
4. Skidmore F, Reich SG. Tardive dystonia. Curr Treat Options Neurol 2005;7:231-6.
5. Kiriakakis V, Bhatia KP, Quinn NP, et al. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121:2053-66.
6. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: Late-onset and persistent dystonia caused by antipsychot-ic drugs. Neurology 1982;32:1335-46.
7. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: Clinical features and management. Hum Psychopharmacol 2008;23:15-26.
8. Llorca PM, Chereau I, Bayle FJ, et al. Tardive dyskinesias and antipsychotics: A review. Eur Psychiatry 2002;17: 129-38.
9. Marsden CD, Quinn NP. The dystonias. BMJ 1990;300: 139-44.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association; 2000.
11. Page D, Butler A, Jahanshahi M. Quality of life in focal, segmental, and generalized dystonia. Mov Disord 2007;22: 341-7.
12. Pekmezovic T, Svetel M, Ivanovic N, et al. Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 2009; 111:161-4.
13. The Dystonia Society. Dystonia and pain. (Available at: www.dystonia.org.uk/Resources/Dystonia/PDF%20Docum ents/Dystonia- pain%20ammended%20new.pdf, accessed August 5, 2010).
14. Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5: 864-72.
15. Gudex CM, Hawthorne MR, Butler AG, et al. Effect of dys-tonia and botulinum toxin treatment on health-related quality of life. Mov Disord 1998;13:941-6.
16. Halbig TD, Gruber D, Kopp UA, et al. Pallidal stimulation in dystonia: Effects on cognition, mood and quality of life. J Neurol Neurosurg Psychiatry 2005;76:1713-6.
17. Lewis L, Butler A, Jahanshahi M. Depression in focal, seg-mental and generalized dystonia. J Neurol 2008;255: 1750-5.
18. Lauterback EC, Freeman A, Vogel RL. Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2004;16:29-36.
19. Pader J. From the dialogue: Dystonia, disability, and depression. Dystonia Medical Research Foundation website (available at www.dystonia- foundation.org/pages/arti-cles-from-the-dystonia-dialogue/221.php?id=16, accessed August 5, 2010).
20. Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 2002;72;608-14.
21. Junker J, Oberwittler C, Jackson D, et al. Utilization and perceived effectiveness of complementary and alternative medicine in patients with dystonia. Mov Disord 2004;19: 158-61.
22. Muller J, Wissel J, Kemmler G, et al. Craniocervical dysto-nia questionnaire (CDQ-24): Development and validation of a disease specific quality of life instrument. J Neurol Neurosurg Psychiatry 2004;75:749-53.
23. Stanilla JK, Simpson GM. Drugs to treat extrapyramidal side effects. In: Schatzberg AF, Nemeroff CB, eds. American Psychiatric Publishing textbook of psychopharmacology, fourth edition. Arlington, VA: American Psychiatric Publishing; 2009:669-94.
24. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. J Clin Psychiatry 2010;71:463-74.
25. Rao AS, Camilleri M. Review article: Metoclopramide and tardive dsykinesia. Aliment Pharmacol Ther 2010;31:11-19.
26. Kaplan S, Staffa JA, Dal Pan GJ. Duration of therapy with metoclopramide: A prescription claims data study. Pharmacoepi Drug Saf 2007;16:878-81.
27. Kenney C, Hunter C, Davidson A, et al. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008;48:379-84.
28. Letter from U.S. Food and Drug Administration. (Available at www.fda.gov/downloads/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/UCM111376.pdf, accessed August 9, 2010).
29. Stanley M, Wilk S. Striatal DOPAC elevation predicts antipsychotic efficacy of metoclopramide. Life Sci. 1979;24: 1907-12.